X4 Pharmaceuticals, Inc. XFOR NASDAQ

X4 Pharmaceuticals, Inc. (XFOR) reported total assets of $290.46M and total liabilities of $104.17M for fiscal year 2025, resulting in total equity of $186.29M.

The company held $253M in cash and short-term investments. Total debt stood at $77.29M, with net debt of $-139.76M. The Debt-to-Equity (D/E) ratio was 0.41 (conservative).

Current ratio is 10.16, indicating strong short-term liquidity. Interest coverage is -9.8x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (50/100) — Total assets $290.46M and equity $186.29M support the company's competitive scale
• VALUE (88/100) — Debt-to-Equity 0.41 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.

TERN

Terns Pharmaceuticals, Inc.

$52.71

+0.06%

DAWN

Day One Biopharmaceuticals, Inc.

$21.47

+0.05%

INZY

Inozyme Pharma, Inc.

$4.00

+0.25%

ABOS

Acumen Pharmaceuticals, Inc.

$2.72

+1.49%

PDSB

PDS Biotechnology Corporation

$1.36

+28.30%

MREO

Mereo BioPharma Group plc

$0.34

+2.98%

ELEV

Elevation Oncology, Inc.

$0.37

-2.12%

HOOK

HOOKIPA Pharma Inc.

$1.11

-1.34%